Drug Trial Radar · NCT06794957
A Study of AL8326 in Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
158
Planned (sponsor's estimate)
Start
May 19, 2022
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Advenchen Laboratories, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.
Conditions
- Non-small Cell Lung Cancer
Interventions
AL8326 tabletsDrug
10mg/tablet;Oral administration, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate (ORR)Time frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medicaal University
Bengbu, Anhui, China
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Xuancheng People´s Hospital
Xuancheng, Anhui, China
Anyang Cancer Hospital
Anyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Nanjing Chest Hospital
Nanjing, Jiangsu, China
Sir Run Run Shaw Hospital (SRRSH),affiliated with Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First Hospital Of Jiaxing
Jiaxing, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.